Investigating the effect of curcumin supplementation on depression, anxiety, pain and BDNF serum concentration in patients with gastrointestinal cancer

Determining the effect of curcumin supplementation on depression, anxiety, pain and BDNF serum concentration in patients with gastrointestinal cancer, treated in hospitals covered by Zahedan University of Medical Sciences.

A concealed, randomized, blinded, sham controlled clinical trial with a parallel group

In this research, 64 patients with gastrointestinal cancer referred to the hospitals covered by Zahedan University of Medical Sciences were included in the study. Then, the patients were divided into two intervention and placebo groups using the permutation block stratified randomization method (patients were matched in terms of age and blinding was double-blind, with blinding of the researcher and statistical consultation).

In this study, male patients over 18 years of age, who have passed at least 6 months since the onset of the disease and met the criteria of depression according to DSM-V criteria and did not have contraindications for curcumin consumption, were included in the study. Also, in this research, patients with end-stage cancer, or with panic disorder, bipolar disorder, co-occurring obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder, or any substance abuse or dependence disorder, and people at high risk of suicide or patients with Clinical diseases such as diabetes, autoimmune diseases, cardiovascular diseases, high blood pressure, Alzheimer's disease, Parkinson's disease, stroke and multiple sclerosis, chronic fatigue syndrome, fibromyalgia and asthma were excluded from the study.

Curcumin group - placebo group

Depression, anxiety, pain, BDNF

Random assignment of patients to two groups is done by permuted block stratified randomization method. In this study, first, a replacement block sample was designed by R statistical software, and the studied population will be included in the study after being examined in terms of entry and exit criteria.

In this research, the double-blind method is used, So the researcher and statistical consultant will not be aware of the desired intervention. In fact, after entering the research, the patients will be blinded by the person responsible for implementing the plan, and during the research, the researcher responsible for the treatment of the patients and the data analyst will not be aware of the names of the groups, and the groups will be named with English letters.

All data is from the proposal, raw data and project reports.

Data is available from the legal system six months after publication for two years

All persons will be able to access the Zahedan University of Medical Sciences's request to the Kurdistan University of Medical Sciences.

For legal issues and the need to use data in future studies

Dr. Yalda Sargazi

After submitting a request to the Zahean Research and Technology Dept. of Science and Technology, a call for submission is given.